---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-149301"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2023-05-19T23:59:59+00:00"
generated_at: "2026-06-14T19:50:26.933832+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aeglea BioTherapeutics terminates CEO & GC; CFO Alspaugh appointed President

## Summary
- President/CEO Jeffrey Goldberg and General Counsel Jim Kastenmayer terminated effective May 16, 2023.
- Additional severance: $50k to Goldberg, ~$34k to Kastenmayer; Kastenmayer retained as consultant for strategic alternatives.
- CFO Jonathan Alspaugh appointed President and principal executive officer.
- Retention bonus for Alspaugh up to $222,500 plus performance-based cash payment estimated ~$250k linked to strategic alternatives outcome.

## SEC filing metadata
- accession: 0001193125-23-149301
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2023-05-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312523149301/0001193125-23-149301-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312523149301/d458588d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-149301
- JSON: https://secwatch.observer/filing/0001193125-23-149301.json
- Plain text: https://secwatch.observer/filing/0001193125-23-149301.txt

## Key facts
- Executive change
  Jeffrey Goldberg was terminated as President and Chief Executive Officer at Spyre Therapeutics, Inc..
  - Action: terminated
  - Role: President and Chief Executive Officer
  source text: Effective May 16, 2023, the employment of each of Mr. Jeffrey Goldberg, the President and Chief Executive Officer of Aeglea BioTherapeutics, Inc. (the “Company”), and Mr. Jim Kastenmayer, the General Counsel of the Company, was terminated.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523149301/0001193125-23-149301-index.htm
- Executive change
  Jonathan Alspaugh was appointed as President at Spyre Therapeutics, Inc..
  - Action: appointed
  - Role: President
  source text: In connection with Mr. Goldberg’s departure, the Board appointed Mr. Jonathan Alspaugh, the Company’s Chief Financial Officer, as the Company’s President and principal executive officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523149301/0001193125-23-149301-index.htm
- Executive change
  Jim Kastenmayer was terminated as General Counsel at Spyre Therapeutics, Inc..
  - Action: terminated
  - Role: General Counsel
  source text: Effective May 16, 2023, the employment of each of Mr. Jeffrey Goldberg, the President and Chief Executive Officer of Aeglea BioTherapeutics, Inc. (the “Company”), and Mr. Jim Kastenmayer, the General Counsel of the Company, was terminated.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523149301/0001193125-23-149301-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.